Cellarity

Had a great conversation with Moira Gunn about how Flagship Pioneering’s Cellarity has been using #artificialintelligence to create its candidate medicines, aiming to dramatically improve probability of success in the clinic.

#medSCAI2024 is happening on Tuesday (Oct. 22) featuring industry leaders talking about all aspects of #AI-powered drug discovery from data through to the clinic.  I am excited to hear from Aviv Regev and other speakers, and to have the keynote moderated by Ryan Cross, Senior Science Correspondent for Endpoints News. See you there!   Grab your ticket today ➡️ https://bit.ly/3yOdJEL   #BiggerLeaps #MachineLearning #ArtificialIntelligence

⏰ Only 8 days until #medSCAI24! Register for this symposium on the cutting edge of medicines, single cell and #AI and #MachineLearning.    Secure your spot ➡️ https://bit.ly/3yOdJEL   #BiggerLeaps

Thrilled to announce our #medSCAI24 keynote panel: “Identifying and Solving the Hard Challenges to Realizing the Full Translational Impact of AI on Drug Discovery/Development.” Moderated by Endpoints News’ Sr. Science Correspondent Ryan Cross, panelists include Jen Nwankwo, Ph.D. of 1910 Genetics, Rory Kelleher of NVIDIA, Peter Clark, PhD of Novo Nordisk, Caroline Gubser Keller of Novartis and Cameron Trenor, MD of Cellarity, who will discuss how to push the applications of AI and ML in medicine forward. Register today ➡️ https://bit.ly/3yOdJEL #BiggerLeaps

What topics do you want discussed at #medSCAI24? There’s a lot to cover on the topics of medicines, single cell and #AI. Shape the conversation by voting in our poll. Register Here ➡️ https://bit.ly/3yOdJEL   #ComputationalResearch #MachineLearning #ArtificialIntelligence #BiggerLeaps

Attend #medSCAI24—our third annual symposium on medicines, single cell technology and #AI! Join esteemed industry leaders for two sessions focused on AI and #MachineLearning-powered #DrugDiscovery.   Hear from Arpeggio Biosciences CEO Joey Azofeifa and professors Paul Blainey, from MIT Department of Biological Engineering, and Cole Trapnell, from University of Washington’s Department of Genome Sciences in ‘Session 1: From Data to New Biology.’   Caroline Gubser Keller, Global Head of Data Science at Novartis BioMedical Research, will lead ‘Session 2: From Biology and Computation to Translation’ with a discussion about innovative applications of AI and ML.   Register Today ➡️ https://bit.ly/3yOdJEL

How are #AI and machine learning revolutionizing #DrugDiscovery? In the latest Data in Biotech podcast episode, hear from Cellarity's Chief Data Officer Parul Bordia Doshi about the latest challenges and innovations driving this transformation, the importance of robust data frameworks and why you should never “think alone.”   🎙 Listen to the full episode: https://lnkd.in/en3VtW4r

We’re pleased to announce our third annual symposium on October 22, 2024! The Medicines, Single Cell and AI (medSCAI) Symposium (formerly known as SCAIM) will bring together the brightest minds in #AI and #MachineLearning to tackle barriers to using single-cell technologies, big data and AI/ML-driven analyses to ultimately bring innovative medicines to patients quicker. Register today to secure your seat and hear from luminaries such as Aviv Regev of Genentech our keynote speaker this year! https://lnkd.in/ddxuVCt5 #BiggerLeaps #ArtificialIntelligence

Our CEO Fabrice Chouraqui tells Pharmaceutical Executive how our cutting-edge platform is transforming the treatment of MASH in partnership with Novo Nordisk. The future of medicine is here, and our platform is leading the way.    Learn more: https://bit.ly/3WeCjpM    #MASH #DrugDiscovery #MachineLearning #AI #SingleCell 

Cellarity CEO Fabrice Chouraqui joins the Biotech2050 Podcast to discuss Cellarity’s dynamic future and how #AI and #MachineLearning are revolutionizing pharma and drug discovery. 🎙️Listen to the full episode:  https://lnkd.in/eSwDJJsu